That's hilarious. That trial was to do with expanding the volume of cord blood, not efficacy, and MSB have already written of that indication to zero!
Maybe you should look at the CHF trial which was written up in Circulation - and absolutely savaged by the editorial.
That's hilarious. That trial was to do with expanding the volume...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.39 |
Change
0.000(0.00%) |
Mkt cap ! $1.581B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.42 | $1.38 | $3.491M | 2.506M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 21684 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 87774 | 11 |
View Market Depth
| Last trade - 15.28pm 10/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |